| Literature DB >> 30661654 |
Stefania Morganti1, Paolo Tarantino1, Emanuela Ferraro1, Paolo D'Amico1, Giulia Viale1, Dario Trapani1, Bruno Achutti Duso1, Giuseppe Curigliano2.
Abstract
The finalization of the Human Genome Project in 2003 paved the way for a deeper understanding of cancer, favouring a faster progression towards "personalized" medicine. Research in oncology has progressively focused on the sequencing of cancer genomes, to better understand the genetic basis of tumorigenesis and identify actionable alterations to guide cancer therapy. Thanks to the development of next-generation-sequencing (NGS) techniques, sequencing of tumoral DNA is today technically easier, faster and cheaper. Commercially available NGS panels enable the detection of single or global genomic alterations, namely gene mutation and mutagenic burden, both on germline and somatic DNA, potentially predicting the response or resistance to cancer treatments. Profiling of tumor DNA is nowadays a standard in cancer research and treatment. In this review we discuss the history, techniques and applications of NGS in cancer care, under a "personalized tailored therapy" perspective.Entities:
Keywords: Driver mutations; Liquid biopsy; Next generation sequencing; Precision medicine; Predictive biomarkers; Tumor heterogeneity; Tumor mutational burden
Mesh:
Year: 2018 PMID: 30661654 DOI: 10.1016/j.critrevonc.2018.11.008
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN: 1040-8428 Impact factor: 6.312